Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus.
Morand EF, Pike M, Merrill J, F van Vollenhoven R, Werth VP, Hobar C, Delev N, Shah V, Sharkey B, Wegman T, Catlett I, Banerjee S, Singhal S. Morand EF, et al. Among authors: delev n. Expert Opin Investig Drugs. 2024 May;33(5):431-440. doi: 10.1080/13543784.2024.2337736. Epub 2024 May 29. Expert Opin Investig Drugs. 2024. PMID: 38807572
Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce.
Connelly K, Eades LE, Koelmeyer R, Ayton D, Golder V, Kandane-Rathnayake R, Gregory K, Brunner H, Burke L, Arnaud L, Askanase A, Aranow C, Vital E, Pons-Estel G, Dantata K, Andersen J, Cornet A, Buie J, Sun Y, Tanaka Y, Simon L, Lahoud Y, Friedman A, Kalunian K, Zuraw Q, Werth V, Garces S, Morand EF; TRM-SLE Consortium. Connelly K, et al. Nat Rev Rheumatol. 2023 Sep;19(9):592-602. doi: 10.1038/s41584-023-00993-7. Epub 2023 Jul 11. Nat Rev Rheumatol. 2023. PMID: 37433880 Review.
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, Delev N, Shah V, Sharkey B, Wegman T, Catlett I, Banerjee S, Singhal S. Morand E, et al. Among authors: delev n. Arthritis Rheumatol. 2023 Feb;75(2):242-252. doi: 10.1002/art.42391. Epub 2022 Nov 11. Arthritis Rheumatol. 2023. PMID: 36369798 Free PMC article. Clinical Trial.
Biological impact of iberdomide in patients with active systemic lupus erythematosus.
Lipsky PE, Vollenhoven RV, Dörner T, Werth VP, Merrill JT, Furie R, Petronijevic M, Velasco Zamora B, Majdan M, Irazoque-Palazuelos F, Terbrueggen R, Delev N, Weiswasser M, Korish S, Stern M, Hersey S, Ye Y, Gaudy A, Liu Z, Gagnon R, Tang S, Schafer PH. Lipsky PE, et al. Among authors: delev n. Ann Rheum Dis. 2022 Apr 27;81(8):1136-42. doi: 10.1136/annrheumdis-2022-222212. Online ahead of print. Ann Rheum Dis. 2022. PMID: 35477518 Free PMC article.
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
Merrill JT, Werth VP, Furie R, van Vollenhoven R, Dörner T, Petronijevic M, Velasco J, Majdan M, Irazoque-Palazuelos F, Weiswasser M, Korish S, Ye Y, Gaudy A, Schafer PH, Liu Z, Agafonova N, Delev N. Merrill JT, et al. Among authors: delev n. N Engl J Med. 2022 Mar 17;386(11):1034-1045. doi: 10.1056/NEJMoa2106535. N Engl J Med. 2022. PMID: 35294813 Clinical Trial.
Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials.
Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, Paris M, Delev N, Teng L, Wollenhaupt J. Mease PJ, et al. Among authors: delev n. ACR Open Rheumatol. 2020 Aug;2(8):459-470. doi: 10.1002/acr2.11156. Epub 2020 Jul 25. ACR Open Rheumatol. 2020. PMID: 32710493 Free PMC article.
22 results